Replies to post #83886 on Anavex Life Sciences Corp (AVXL)

[gburgin]

sokol, you said "the U.S. FDA exclusivity only has application in the U.S. Therefore, the Greek patents have no relation to the FDA exclusivity, "
Yes, I understand all that. My point which was poorly worded was just that for the USA market, the greek patents would have to extend past the exclusivity period to add any value re: protection of AD treatment.